Earlier this year, the Centers for Medicare and Medicaid Services (CMS) issued a proposed rule that would require information about drug costs be included in direct-to-consumer (DTC) advertisements of prescription drugs and biological products. NCCS issued a statement regarding the proposal, saying, “While we understand that CMS is taking small and concrete steps to advance its drug pricing agenda, we do not believe that the DTC proposal will achieve transparency, advance the effort to make Americans more informed health care consumers, or reduce drug prices.”
Below is NCCS’ formal comment letter sent to CMS Administrator Seema Verma, regarding the drug pricing in DTC ads proposed rule.
Read the full NCCS Letter below or view/download it here. (Link opens in new tab.)
Read more NCCS Policy Comments »